Physician profile
Dorin Andreescu
NPI 1669457107
$733.36
in general payments reported to CMS, 2019-2025
12 companies · $134 in 2025
The $134 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $156 · 2020: $22.40 · 2021: $173 · 2022: $231 · 2023: $16.79 · 2025: $134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $151.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $151.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $333.15 | 2020-2022 | |
| E.R. Squibb & Sons, L.L.C. | $93.70 | 2021-2022 | |
| Novo Nordisk INC | $64.97 | 2019-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $61.47 | 2019 | |
| Vapotherm INC | $41.87 | 2019 | |
| Xeris Pharmaceuticals, INC. | $24.97 | 2025 | Gvoke Hypopen |
| Allergan, INC. | $24.96 | 2019 | |
| Abbott Laboratories | $20.57 | 2025 | Freestyle Libre 3 |
| Insulet Corporation | $18.51 | 2025 | Omnipod |
| Dexcom, INC. | $18.42 | 2025 | Dexcom G6 Transmitter |
| Daiichi Sankyo INC. | $16.79 | 2023 | Injectafer |
| Astellas Pharma US INC | $13.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dorin Andreescu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.